Avalo secures IL-1β monoclonal antibody and reveals plans for a private investment round potentially reaching $185M.

Akebia Therapeutics Granted US Regulatory Clearance for Vafseo (vadadustat) Pills, a New Therapy for Adult Anemia Linked to Long-term Renal Failure in Dialysis Patients.

Viking Therapeutics Reports Outcomes of Initial Human Study for Oral Pill Version of Combined GLP-1/GIP Agonist VK2735.

TiumBio Lodges Application for Phase 1b Study of Prolonged-Effect Factor VII Agent TU7710 in Subjects with Hemophilia A/B.

First Subject Receives Initial Treatment in Innovent's Phase III Trial (Neoshot) Evaluating IBI310 (Anti-CTLA-4) with Sintilimab in Pre-Surgery Treatment for High Microsatellite Instability/Mismatch Repair Deficient Colon Cancer.

Tectonic Therapeutics Commences First-Stage Clinical Trial Evaluating TX45 in Category II Lung High Blood Pressure among Subjects Having Conserved Ejection Fraction Cardiac Insufficiency.

FDA Regulators Greenlight Merck's Novel WINREVAIR™ (sotatercept-csrk) Therapy for Treating Pulmonary Arterial Hypertension in Adult Patients.

Atamyo Pharma Secures Approval from European Regulators to Commence Human Trials of ATA-200, Their Innovative Genetic Treatment for Limb-Girdle Muscular Dystrophy 2C/R5.

CinFina Pharma Reveals US Health Authority's Approval for Early-Stage Drug Trial and Commencement of Dosing in Initial Human Subjects for its Obesity Medication, CIN-110.

Astellas Pharma Inc. announced that Japan's Ministry of Health, Labour and Welfare approved VYLOY™ (zolbetuximab), an anti-CLDN18.2 drug, for advanced and inoperable metastatic stomach cancer patients positive for CLDN18.2.

Initial enrollment of patients with stomach and esophageal cancer has begun for a second-stage mixed studies trial, utilizing Affibody's ABY-025 diagnostic tool for positron emission tomography.

Corteria Pharmaceuticals has launched the first stage of clinical trials to assess the efficacy of their CRF2 activator, COR-1167, specifically targeting the progression of cardiac insufficiency.